Comparative temporal and dose-dependent morphological and transcriptional uterine effects elicited by tamoxifen and ethynylestradiol in immature, ovariectomized mice
© Fong et al; licensee BioMed Central Ltd. 2007
Received: 12 February 2007
Accepted: 07 June 2007
Published: 07 June 2007
Uterine temporal and dose-dependent histopathologic, morphometric and gene expression responses to the selective estrogen receptor modulator tamoxifen (TAM) were comprehensively examined to further elucidate its estrogen receptor-mediated effects. These results were systematically compared to the effects elicited by the potent estrogen receptor ligand 17α-ethynylestradiol (EE) to identify pathways similarly and uniquely modified by each compound.
Three daily doses of 100 μg/kg TAM elicited a dose-dependent increase in uterine wet weight (UWW) in immature, ovariectomized C57BL/6 mice at 72 hrs with concurrent increases in luminal epithelial cell height (LECH), luminal circumference and glandular epithelial tubule number. Significant UWW and LECH increases were detected at 24 hrs after a single dose of 100 μg/kg TAM. cDNA microarray analysis identified 2235 differentially expressed genes following a single dose of 100 μg/kg TAM at 2, 4, 8, 12, 18 and 24 hrs, and at 72 hrs after three daily doses (3 × 24 hrs). Functional annotation of differentially expressed genes was associated with cell growth and proliferation, cytoskeletal organization, extracellular matrix modification, nucleotide synthesis, DNA replication, protein synthesis and turnover, lipid metabolism, glycolysis and immunological responses as is expected from the uterotrophic response. Comparative analysis of TAM and EE treatments identified 1209 common, differentially expressed genes, the majority of which exhibited similar profiles despite a temporal delay in TAM elicited responses. However, several conserved and treatment specific responses were identified that are consistent with proliferation (Fos, Cdkn1a, Anapc1), and water imbibition (Slc30a3, Slc30a5) responses elicited by EE.
Overall, TAM and EE share similar gene expression profiles. However, TAM responses exhibit lower efficacy, while responses unique to EE are consistent with the physiological differences elicited between compounds.
Tamoxifen (TAM) treatment is an adjuvant therapy prescribed for estrogen receptor positive breast cancers. TAM and its metabolites, 4-hydroxytamoxifen (4OH-TAM), N-desmethyltamoxifen (DMT) and 4-OH-N-desmethyltamoxifen (endoxifen), exhibit antiestrogenic activities by competitively inhibiting the binding of potent agonists to the estrogen receptor (ER) thus antagonizing their proliferative effects [1–4]. Despite the high therapeutic index of TAM for breast cancer, there are concerns regarding the increased occurrence of uterine cancer as early as 2 years after initiating treatment . Although there is no direct evidence that it initiates or promotes uterine cancer, TAM exhibits partial ER-agonist activity by inducing uterotrophy in immature and ovariectomized rodents [6, 7]. Consequently, a more comprehensive comparison to full agonists is warranted to further elucidate the uterine gene expression effects responsible for its partial agonist activity.
TAM is classified as a selective estrogen receptor modulator (SERM) as a result of its differential effects in breast and uterine tissues . A number of factors influence the specificity and efficacy of SERM-bound, ER-mediated gene expression, and the subsequent physiological effects. This includes differences in tissue-specific ER isoform expression levels, ligand-induced ER topology, chromatin structure, and coactivator expression and distribution [9, 10], thus making the ER an ideal target for drug discovery and development. For example, raloxifene, a second-generation SERM, has been approved for osteoporosis and studies also support its use for breast cancer .
The uterotrophic assay is a well established method to evaluate the estrogenicity of a compound as measured by ER-mediated increases in uterine wet weight making it an ideal model for comparing 17α-ethynylestradiol (EE) and TAM elicited effects . The uterotrophic response also provides well characterized phenotypic hallmarks that facilitate the interpretation of gene expression changes and their function. Early studies have shown that TAM elicits a weaker uterotrophic response than 17β-estradiol (E2) in an immature rodent model , however, the mechanisms for its partial agonist activity are not well understood.
Genome-wide expression analysis, phenotypically anchored to tissue level effects, provides a comprehensive strategy to identify differential gene expression important in the ER-induction of uterine wet weight. In this report, we extend previous studies examining ER-mediated induction of uterine wet weight [14–16] by identifying conserved and divergent uterine tissue and gene expression responses elicited by TAM when compared to EE, an orally active full agonist that mimics the effects of E2 . Comparative analysis found conserved gene expression responses that exhibited lower efficacy, consistent with the weak agonist activity of TAM, as well as divergent responses unique to EE that partially explain the lack of TAM-induced water imbibition.
Morphometric analysis and histopathology
TAM- and EE-induced uterine morphometric changes
Dose Response (3 × 24 hr)
TAM Dose (μg/kg)
Luminal Epithelial Cell Height (μm)
Luminal Circumference (mm)
Avg. Number of Glandular Tubules
8.75 ± 0.86
0.77 ± 0.14
8.99 ± 1.00
0.72 ± 0.12
10.91 ± 2.97
1.17 ± 0.41
10.73 ± 1.15
1.17 ± 0.29
15.12 ± 1.55*
1.87 ± 0.26*
24.58 ± 2.79*
3.60 ± 0.27*
27.08 ± 3.79*
2.68 ± 1.19*
31.30 ± 2.25*
3.05 ± 0.73*
28.94 ± 3.35*
Time Course (100 μg/kg)
Luminal Epithelial Cell Height (μm)
Luminal Circumference (mm)
9.98 ± 1.68
0.79 ± 0.19
8.61 ± 1.58
0.80 ± 0.06
10.06 ± 2.50
0.96 ± 0.29
9.46 ± 1.28
0.99 ± 0.21
9.18 ± 1.03
1.29 ± 0.42
11.08 ± 1.94*
1.22 ± 0.42
3 × 24
28.61 ± 7.50*
2.85 ± 1.83*
Uterine endometrial glands synthesize and secrete fluids in preparation for conceptus, implantation and growth. Significant increases in the number of glands was observed at 30 μg/kg TAM (Table 1A) in the absence of a dose responsive increase, which may be an artifact of histological sampling of the uterine horn. Similarly, EE-treated uteri exhibited an increased number of endometrial glands that was not statistically significant.
Uterine gene expression changes elicited by tamoxifen
Differentially expressed genes in the dose and time dependent studies were identified based on their empirical Bayes posterior probability of activity [P1(t)-value] on a per-gene, per-time point basis. P1(t)-values approaching 1.0 indicate a greater likelihood of treatment-related differential gene expression. Using P1(t) > 0.999 and |fold change| ≥ 1.5 as selection criteria, a prioritized list of 2941 features, representing 2235 unique Entrez Gene annotated genes, were identified in the temporal study with 55% of the genes exhibiting induction and 45% repression (Additional file 1). Differential expression levels ranged from 14.3-fold repression (tight junction protein 4, Tjp4) to 28.1-fold induction (arginase 1, Arg1), further demonstrating the responsiveness of the uterus to tamoxifen. Using the same selection criteria (P1(t) > 0.999 and |fold change| of ≥ 1.5) at a minimum of three doses, to ensure dose responsiveness, 1630 features, representing 1036 unique Entrez Gene-annotated genes, exhibited dose dependent expression (Additional file 2). Of the 1036 genes exhibiting a dose-dependent response at 3 × 24 hrs and of the 738 differentially expressed genes at 3 × 24 hrs in the time course study, 691 genes (94%) were in common, demonstrating good reproducibility between experiments.
Comparison of common temporal TAM and EE gene expression data
Classification of TAM and EE commonly active annotated features
Number of Annotated Genes
Similar profiles exhibit patterns which are comparable in direction and magnitude across time; this also takes into account temporally shifted responses.
EE Efficacious (EEf)
Potent responses demonstrate similar directional responses, but one compound elicits a greater induction or repression, by at least 2-fold, than the other; this category also includes temporally shifted responses.
TAM Efficacious (TEf)
Gene pairs which did not fall into the previous four categories were labeled as Ambiguous
TAM and EE responsive genes were also examined for estrogen response elements (EREs) in their promoter regions by comparison to a list of computationally identified sequences . EREs were found in 176 TAM-active genes and 218 EE-active genes, with 133 regulated by both compounds. Only 10% of TAM or EE differentially expressed genes possessed an ERE suggesting that other trans- acting factors may also be involved or that EREs were outside of the search regions. Annotation information in public repositories is constantly evolving, thus gene names may have changed or new genes may have been added since the publication. As a result, some genes may be misclassified regarding their ERE status.
TAM- and EE-specific gene expression data
The pathways represented within unique EE-responsive genes include apoptosis regulators (Bok and Pdcd6) and water imbibition (Aqp8 and Slc22a7), consistent with the physiological effects observed. Fewer unique TAM-responsive genes were identified. There was not an overrepresentation of any functional pathway consistent with its weaker uterotrophic response. These data suggest that differentially regulate subsets of genes exist that contribute to the distinctive uterotrophic response elicited by each treatment.
A comparative approach was used that integrates the gross organ, histopathological, and morphometric uterine effects of EE and TAM with their dose response and temporal gene expression profiles to further elucidate the molecular basis of the partial agonist activity of TAM. TAM treatment induces a 5-fold increase in gross uterine weight following three daily doses compared to an 11-fold increase with EE. In addition, no significant water imbibition was induced by TAM. These effects are well documented and are the basis for the classification of TAM as a partial agonist [6, 19, 20, 25]. Moreover, TAM induces a delayed increase in uterine weight when compared to EE which may be partially attributed to its weaker agonist activity but is more likely a reflection of slower absorption [26–28]. In contrast, peak serum levels of EE are detected within two hours of treatment .
At equi-efficacious doses of TAM and EE (i.e. 100 vs. 20 μg/kg, respectively), comparable effects on UWW, luminal circumference and glandular epithelial were observed (data not shown), suggesting both treatments proceed through similar changes to achieve uterotrophy. However, at higher doses, TAM does not elicit a comparable gamut of responses as seen with higher doses of EE. Surprisingly, TAM increased luminal epithelial thickness , due to cellular hypertrophy and hyperplasia, that was not significantly different from EE, but mediated a smaller increase in luminal circumference with more endometrial glands compared to EE. Although these results appear contradictory, glandular epithelium may arise from the luminal epithelium and appear as highly invaginated regions of the lumen that generate a large secretory surface area . Thus, despite fewer endometrial glands in EE samples, its glandular area is greater due to the increased luminal glandular surface area which was not observed in the TAM treated samples.
Temporal tamoxifen-elicited gene expression profiles were examined following a single dose as well as after three daily doses of 100 μg/kg TAM. Only 9 features, representing 6 annotated genes, exhibited differential expression at 2 and 4 hrs after TAM treatment compared to 1234 EE genes at the same time points , consistent with the delayed histological effects. Of these early TAM responses, only Esr1 and Car3 have been reported to be induced by estrogen [16, 31]. At 12 hrs, 683 genes were differentially expressed in response to TAM, of which 541 genes were also affected by EE between 2 and 8 hrs . Agglomerative hierarchical clustering suggests that genes affected by TAM and EE exhibited comparable gene expression changes despite the delay in TAM responses.
Genes regulated by TAM and EE represent a variety of pathways including cell cycle regulation, cytoskeletal re-organization, nucleotide metabolism, immune and complement activation and lipid transport and metabolism, and have previously been associated with eliciting the uterotrophic response [15, 16, 22, 32–34]. Similarities in their gene expression profiles suggest that the uterotrophic response involves a defined subset of genes mediated by the ER. Furthermore, greater than 75% of TAM-activated genes that possessed an ERE, were also activated by EE. However, differences in efficacy and responsive genes may partially explain uterotrophic response differences.
Despite temporal delays, many genes were regulated by both EE and TAM. Most of these commonly active genes exhibited comparable fold changes suggesting that they do not significantly influence the magnitude of the uterotrophic response. For instance, both treatments equally repressed uterotrophic supportive pro-apoptotic caspases (Casp2 and Casp6) (reviewed in ). Although these genes were responsive to EE and TAM, others demonstrated quantitative differences in their expression behavior. Twenty-eight genes, including the proliferation supportive genes Cdkn1a, Fos and Inhbb, exhibited greater EE efficacy consistent with their previously reported estrogen-induced expression [36–38] resulting in a full uterotrophic agonist response. In contrast, 22 genes more highly induced by TAM included G2/M inhibitor (Sfn/14-3-3σ), which has been associated with human endometrial carcinomas  to reduce proliferation. Many of these quantitative differences in gene expression efficacy are consistent with the potent agonist activity of EE and the weak agonist activity of TAM.
There were also treatment-specific gene expression effects. Tentatively, 240 and 60 modulated genes were identified as unique to EE or TAM, respectively. In general, these responses were consistent with uterotrophic activity elicited by EE and TAM. For example, QRT-PCR verified the early induction of mitotic gene, Anapc1 by EE (data not shown). Also, the treatment specific repression of pro-apoptotic Bcl-2 member, Bok, and the induction of Pdcd6, an apoptosis regulator, associated with proliferating tissues  are consistent with the greater efficacy of EE. Bok has previously been shown to be EE responsive in uteri, whereas Pdcd6 approached the statistical cut-off in a previous study . For TAM, QRT-PCR confirmed decreased expression of Sipa1 (data not shown), a repressed response at 24 hrs associated with decreased proliferation  that may reduce hyperplasia.
DNA synthesis and replication pathways were also differentially regulated. Sustained up-regulation of dNDP phosphorylating genes, Nme1 and Nme6 , suggest salvage pathways are emphasized for nucleotide synthesis rather than de novo processes where Prps1, the first step in purine biosynthesis, is repressed during the same period. These genes are similarly modulated by TAM and EE suggesting that proliferation may deplete resources for de novo synthesis. Only Nme1 has been previously shown to be EE responsive in rodent uteri [15, 16]. However, EE uniquely inhibited the de novo pyrimidine synthesis gene, Dhodh [18–72 hrs], and induced the nucleotide recycling gene, Nt5m [18 and 72 hrs]  suggesting an involvement of salvage pathways to support EE-induced proliferation which have not previously been reported to be estrogen responsive.
Water imbibition is a characteristic uterine response to estrogens involving the increased flow of water to the lumen mediated by aquaporins and ion transporters . It does not appear to be a factor in TAM-induced uterine weight increases as blotted weights were not significantly different from wet weights. Aqp1 and Aqp5 are comparably regulated by TAM and EE, while Aqp8 induction was specific to EE (QRT-PCR verified, data not shown). Aqp8 is a known contributor to water imbibition  and its EE-specific response suggests it may play a larger role in the process of a full uterotrophic response.
The lack of ion transporter regulation may also be a contributing factor in the absence of TAM-induced water imbibition. The EE induction of zinc transporter, Slc30a3 [12 hrs], which causes ion uptake into various vesicle compartments [46, 47] may facilitate stromal edema and has been shown to be responsive to estrogen where it is down-regulated in brain tissue . Organic anion transporter, Slc22a7, was repressed by EE from 18 – 72 hrs in the uteri suggesting anion retention in the stroma that may also be important for edema. Slc22a7 is an importer in the basolateral membrane of kidney tubule epithelia (reviewed in ), and is estrogen responsive in the kidney .
Differential regulation of ATP production genes is also consistent with the greater uterotrophic efficacy of EE. Transcripts associated with oxidative phosphorylation (OXPHOS) complex I, Ndufb8 [8–24 hrs], and complex III, Uqcr [8–18 hrs] and Uqcrh [4–18, 72 hrs], were all up-regulated. Although not previously been reported as responsive, collectively, the EE modulation of OXPHOS components is consistent with greater energy demands required to support increasing hypertrophic and hyperplastic activity induced by EE compared to TAM.
Other TAM gene expression studies have been conducted using in vitro breast cancer models, primarily MCF-7 cells. Comparisons of differentially expressed gene lists identified minimal to no overlap of TAM responses between in vitro human breast tissue and in vivo mouse uterus [51, 52]. Only the induction of Uqcrb , Nqo1 , Tff1, Mapt , Pctk3, Wnt4 , Myb, Cdc6, Cdc20, Mcm2, Fos and Mybl2  and repression of Xrcc1, Tgfa , Rap1ga1, Blnk, Tm4sf1, Matn2, Ifi30, Tgfb3 and Smpd1  correlated with the changes observed in the current study. Moreover, there are examples of divergent gene expression changes such as inverse responses for Pfn2 , Ctsh, Selenbp1, Nfrkb, Cyp1a1 , Prps1 and Tmsb4x . The long term uterine effects of TAM have also been examined in mice following neonatal exposure. Mice were treated for four consecutive days after treatment and uteri samples examined at various months after dosing . Col1a1 exhibited persistent up-regulation months after treatment and was also induced in our short term study. Several factors, in addition to model differences, likely contribute to the minimal overlap including differences in array platforms and genome coverage, study design, and data analysis. For example, E2 and 4OH-TAM were utilized in the in vitro studies while EE and TAM were administered to the mice.
Despite the minimal overlap between the models, the activities of TAM, when compared to E2 were comparable. In vitro and in vivo, the gene expression changes elicited by 4OH-TAM were similar to those mediated by E2 in MCF-7 cells. Furthermore, the magnitude of gene expression changes due to 4OH-TAM was attenuated compared to E2 [55, 57]. Although 4OH-TAM and EE induced similar cell cycle genes, other down-stream mechanisms were also regulated to prevent 4OH-TAM mediated cell cycle progression . Some of these mechanisms may play a roll in the partial uterotrophic response elicited by TAM in treated mice.
Differences in chemical structure may also contribute to ligand specific responses. TAM belongs to the stilbene/triphenylethylene family while EE is steroidal. Each has unique binding modes resulting in different ER conformations , binding affinities [59, 60], ligand-induced binding domain topographies , coactivator recruitment capabilities [62, 63], gene-specific thresholds of activation, and efficacies . Specifically, 4OH-TAM induces a different conformational change in the ER compared to E2, influencing interactions with different coactivators. Electrophoretic mobility shift assay and crystallographic examination  have shown that 4OH-TAM-bound ER could not bind a GRIP1 coactivator LXXLL peptide due to helix-12 interference at the binding cleft, which was recruited by E2. Consequently coactivator recruitment may influence receptor complex interactions with response element variants  which has been shown with other structurally diverse ligands and nuclear receptors [67, 68].
In addition, differences in absorption, distribution, metabolism and excretion (ADME) between ligands and species, likely contribute to divergent physiological and gene expression characteristics. It is well documented that TAM metabolism differs significantly between humans and rodents, for example, TAM N-oxide, 4OH-TAM and DMT are the predominant metabolites in the mouse, while DMT is the major human metabolite in microsomal studies [28, 69, 70]. In rodents, the levels and rates of TAM metabolism to 4OH-TAM and DMT were significantly different in the rat and mouse, where the rat metabolite profile more closely resembles human profiles .
A cytochrome P450 2D6 polymorphism in humans further illustrates the potential effects of differences in metabolism on TAM activity. 4-OH-N-desmethyltamoxifen (endoxifen) is a recently identified TAM metabolite, found at higher levels than 4OH-TAM in patient serum, generated by CYP2D6 activity. It exhibits similar ER binding affinity, and comparable breast cancer cell proliferation and estrogen-induced pS2 mRNA expression inhibition activities compared to 4OH-TAM . However, patients expressing specific CYP2D6 polymorphisms (i.e., CYP2D6*3, *4, *5 and *10) that impaired or abolished CYP2D6 metabolism have a nearly 2-fold higher risk of breast cancer recurrence . Collectively, these studies illustrate the significant differences in TAM metabolism between models that compromise the extrapolation of rodent data for use in human risk assessment.
Despite the comprehensive time course and dose response studies, a complete assessment of the gene expression effects and their roles in uterine responses could not be achieved due to limited genome coverage on our custom cDNA arrays and incomplete functional annotation for the represented genes. However, comparative TAM and EE studies using comparable designs and models identified conserved functionally annotated gene expression changes that are consistent with the measured uterotrophic response. Qualitatively, TAM and EE gene expression profiles are similar; however, there are quantitative differences in efficacy, consistent with the partial agonist activity of TAM. Despite the evidence for these qualitative and quantitative differences in gene expression, demonstration that these changes have causal roles in the partial uterotrophic response elicited by TAM is required. The relevance of the differences between estrogen and TAM and the association with endometrial cancer [9, 72, 73] also needs further investigation.
Animal husbandry and treatment
Female C57BL/6 mice, ovariectomized by the vendor on postnatal day (PND) 20, were obtained from Charles River Laboratories (Raleigh, NC) on PND 25. Groups of five mice were housed in polycarbonate cages bedded with cellulose fiber chips (Aspen Chip Laboratory Bedding, Northeastern Products, Warrensberg, NY) in a 23°C environment with 30–40% humidity and a 12 h light/dark cycle (0700 – 1900 h). Animals had access to deionized water and Harlan Teklad 22/5 Rodent Diet 8640 (Madison, WI) ad libitum and acclimatized for 4 days prior to treatment. For the dose response study, animals (n = 5) were orally gavaged with 0.1 mL of 1, 3, 10, 30, 100, 300 or 1000 μg/kg b.w. tamoxifen (≥ 99% pure, trans-2- [4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine) (Sigma Chemicals, St. Louis, MO), 100 μg/kg b.w. 17α-ethynylestradiol (EE; 17α-Ethynyl-1,3,5(10)-estratriene-3,17β-diol) (Sigma) or sesame oil vehicle (Sigma) alone. Standard uterotrophic regimen was followed , consisting of three daily doses followed by sacrifice 24 hrs after the final treatment, (3 × 24 hrs). Doses were prepared based on average animal weight. For the time course study, animals (n = 5) were orally gavaged once or three times daily (3 × 24) with 100 μg/kg b.w. TAM or vehicle alone and sacrificed at 2, 4, 8, 12, 18 and 24 hrs after treatment in addition to 3 × 24 hrs treatment group. Animals were sacrificed by cervical dislocation and animal body weights were recorded. The uterus was transected at the border of the cervix, and stripped of extraneous connective tissue and fat. Whole uterine weights were recorded before (wet weight) and after blotting (blotted weight) under pressure with absorbent tissue. A 6–8 mm section of uterine horn was not blotted and placed in 10% neutral buffered formalin (NBF) for histological preparation while the remainder was snap frozen in liquid nitrogen and stored at -80°C for RNA extraction. All procedures were performed with the approval of the Michigan State University All-University Committee on Animal Use and Care.
Histological processing, morphometric and pathological analysis
Samples stored in 10% NBF were allowed to fix for at least 24 hrs at room temperature then placed into tissue cassettes and stored in 30% ethanol holding solution at 4°C. Paraffin embedding, 5 μm sectioning, mounting and hematoxylin and eosin staining were completed by the Michigan State University Laboratory for Anatomical Histology and Molecular Sciences according to standard techniques . Pathological assessments were evaluated according to standardized National Toxicology Program (NTP) pathology codes.
Morphometric analysis was performed on midhorn uterine cross sections for all animals (n = 5 per treatment group) using Scion Image analysis software (Scioncorp, Frederick, MD). Histological markers of uterotrophy, including luminal epithelial cell height (LECH), luminal circumference and number of endometrial glands were quantified for each slide. Statistical analysis of morphometric data was assessed by Dunnett's or two-way ANOVA followed with Tukey's HSD post hoc analysis to examine dose dependent and temporal effects, respectively (SAS version 9.1).
Briefly, 1.0 mL of Trizol (Invitrogen, Carlsbad, CA) was added to the frozen uterine tissue in a 2.0 mL microfuge tube and homogenized in the presence of steel beads by a Mixer Mill 300 homogenizer (Retsch, Germany). Total RNA was isolated and extracted according to the manufacturer's protocol and resuspended in The RNA Storage Solution (Ambion, Austin, TX). RNA samples were quantified spectrophotometrically (A260) and assessed for quality by A260/A280 ratio as well as inspected using denaturing agarose gel electrophoresis.
Microarray hybridization and analysis
Custom in-house cDNA arrays consisting of 13,361 features, representing 7,952 unique genes (Unigene Build 144), were spotted on epoxy coated glass slides (SCHOTT Nexterion, Germany) using an Omnigrid arrayer (GeneMachines, San Carlos, CA) and Telechem Chipmaker 3 pins in a TeleChem CHP3 printhead head (Telechem International Inc., Sunnyvale, CA) by the Research Technology Support Facility at Michigan State University . Selected clones were obtained from EPAMAC , Research Genetics, the National Institute of Aging and Lion Biosciences. Detailed protocols for processing of microarrays are available at .
An independent reference study design was used to assess treatment effects . For the dose response study, each treatment group was hybridized to a single vehicle pool utilizing 14 arrays, including dye swaps, and 3 biological replicates for a total of 42 arrays. For the time course study, each time-matched treated and vehicle sample was competitively hybridized utilizing 14 arrays, including dye swaps with 3 biological replicates for a total of 42 arrays. The Genisphere 900 3DNA Array Detection (Genisphere Inc., Hatfield, PA) indirect incorporation kit was used to generate cDNA samples for hybridization. Briefly, 1 μg of RNA was reverse transcribed in the presence of an oligo-tagged primer specifically targeted for Cy3- or Cy5- conjugated dendrimers. The cDNA was resuspended in 58 μL of 2X Formamide-Based Hybridization Buffer and hybridized overnight on arrays sealed in a light-shielded, humid chamber submerged in a 42°C water bath incubation. Slides were then washed in SSC solutions containing decreasing concentrations of SDS, spin-dried and re-hybridized with a Cy3:Cy5 (1:1) dendrimer mixture in formamide based buffer to indirectly incorporate dyes at the Cy3- and Cy5-dendrimer-tagged cDNA hybridized on the first day. Slides were washed and dried as previously described, and scanned at 635 nm (Cy3) and 532 nm (Cy5) using a 428 Affymetrix Scanner (Santa Clara, CA). Images were examined, features identified and intensity values recorded using GenePix v.5.1 (Molecular Devices).
Microarray quality control, statistical analysis and gene list filtering
All arrays in this study were compared to a historical data set of high quality arrays. Parameters assessed included background signal intensity, feature signal intensity, feature vs. background signal intensity ratios, the number of features with background intensities greater than the feature intensity for each array, and relationships between feature and background signal intensities. All arrays surpassed the quality control parameters established in this laboratory .
Data were normalized using a semi-parametric approach  and model-based t-values were calculated comparing time-matched treated and vehicle samples. Posterior probabilities of activity [P1(t)-value] were then calculated on a per-gene and per-time point basis using an Empirical Bayes analysis . Gene lists were initially filtered based on posterior probability (P1(t) > 0.999) and fold-change cut-off (|fold change| > ± 1.5) resulting in an active gene list on which further functional analysis was conducted. All raw and analyzed data were stored in dbZach , a Minimum Information About Microarray Experiments (MIAME)-supportive relational database  running under Linux/Oracle 10 g. dbZach currently supports microarray data storage, retrieval, and querying as well as facilitates data analysis, sharing and reporting .
Active gene lists exclusive to TAM and EE were also generated. Data for the EE time course has previous been published . The TAM unique gene list was generated based on relaxed criteria (P1(t) > 0.9 and |fold change| > ± 1.4 cut-off) to obtain a liberal EE-mediated gene list which was then excluded from the original TAM unique gene list using P1(t) > 0.999 and |fold change| > ± 1.5 criteria. The EE unique gene list was generated using a reciprocal approach (i.e., relaxed criteria (P1(t) > 0.9 and |fold change| > ± 1.4 cut-off) to obtain a liberal TAM-mediated gene list which was then excluded from the original EE unique gene list using P1(t) > 0.999, and |fold change| > ± 1.5 criteria). This approach ensured that genes marginally missing the cut-offs were not included in the compound-unique list.
Estrogen response element searches were completed by comparing Gene Symbols to the computationally identified list compiled by Bourdeau et al. .
Aliquots of RNA isolated from each of the five replicates were set aside for SYBR™ Green quantitative real-time PCR (QRT-PCR) verification. EE-treated, temporal mouse uteri RNA were previously isolated . An oligo-dT anchored Superscript II (Invitrogen) reverse transcriptase reaction was carried out on 1 μg of RNA, in a 20 μL reaction, from each biological sample as per manufacturer's instructions. Samples were diluted four-fold and 3 μL used in a 30 μL real-time reaction mix containing 1X SYBR Green PCR buffer, 3 mM MgCl2, 0.33 mM dNTPs, 0.5 IU AmpliTaq Gold (Applied Biosystems, Foster City, CA) and 0.15 mM forward and reverse primer. All primers were designed by submitting cDNA microarray clone sequences into Primer3  to obtain an amplicon of approximately 125 bp (Additional file 6). PCR amplification was conducted in 96-well MicroAmp Optical plates (Applied Biosystems) on an Applied Biosystems PRISM 7000 Sequence Detection System under the following conditions: 10 min denaturation and enzyme activation at 95°C, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. After amplification, a 30 min dissociation protocol was conducted to assess primer specificity and product uniformity. Each plate contained duplicate standards of purified PCR product of known template concentration over eight orders of magnitude to generate a log template concentration standard curve. No template controls (NTC) samples were included on each plate such that experimental samples within 2 standard deviations of the NTCs are considered below the limits of detection. Plots were visualized and thresholds determined using ABI Prism 7000 SDS Software (Applied Biosystems). Results were normalized to a geometric mean of beta-actin (Actb), glyceraldehydes-6-phosphate dehydrogenase (Gapd) and hypoxanthine guanine phosphoribosyl transferase (Hprt) mRNA levels to control for differences in RNA loading, quality and cDNA synthesis. Statistical significance of expression differences between vehicle and TAM treated samples were assessed by two-way ANOVA followed by Tukey's HSD post hoc analysis to examine treatment and treatment over time effects (SAS version 9.1). Correlation analyses of QRT-PCR and microarray data generated using the correlation function of R v2.1.0.
Rabbit polyclonal antibodies specific for PCNA were purchased from Abcam, Inc. (Cambridge, MA) and staining localized using manufacturer's instructions for the Vectastain Elite ABC Kit (Vector Laboratories, Burlingame, CA). Briefly, paraffin-embedded uterine sections were placed on glass slides, deparaffinized in xylene and re-hydrated through a series of decreasing ethanol concentration washes ending in ddH2O. Endogenous peroxidases were quenched in 0.3% H2O2 in methanol solution (30 min) followed by boiling (15 min) in a 10 nM sodium citrate solution (pH 6.0) for antigen retrieval. To minimize nonspecific background staining, sections were blocked with normal goat serum (Vector Laboratories) for 20 min. The slides were incubated for 1 hr with the primary rabbit anti-PCNA polyclonal antibody (1:500 dilution in PBS), followed by 30 min each with biotinylated goat anti-rabbit antibody (Vector Laboratories) (1:400) and ABC reagent (Vector Laboratories). A single PBS rinse was performed between incubations with each antibody. Localization of antigen was obtained using Vector® NovaRED (Vector Laboratories). The sections were counterstained with hematoxylin.
The authors would like to gratefully thank Dr. Jeremy Burt, Dr. Alhaji N'jai, Joshua Kwekel and Suntae Kim for editing and proofing of the manuscript. Funding for this study was provided by NIGMS grant GM075838 to TRZ as well as fellowships from the MSU Biochemistry and Molecular Biology Department to CJF. TRZ is partially supported by the Michigan Agricultural Experiment Station.
- Mandlekar S, Hebbar V, Christov K, Kong AN: Pharmacodynamics of tamoxifen and its 4-hydroxy and N-desmethyl metabolites: activation of caspases and induction of apoptosis in rat mammary tumors and in human breast cancer cell lines. Cancer Res. 2000, 60: 6601-6606.PubMed
- Jordan VC: Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer. Br J Pharmacol. 1993, 110: 507-517.PubMed CentralPubMedView Article
- Wijayaratne AL, Nagel SC, Paige LA, Christensen DJ, Norris JD, Fowlkes DM, McDonnell DP: Comparative analyses of mechanistic differences among antiestrogens. Endocrinology. 1999, 140: 5828-5840.PubMed
- Johnson MD, Zuo H, Lee KH, Trebley JP, Rae JM, Weatherman RV, Desta Z, Flockhart DA, Skaar TC: Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat. 2004, 85: 151-159.PubMedView Article
- Fisher DE: Apoptosis in cancer therapy: crossing the threshold. Cell. 1994, 78: 539-542.PubMedView Article
- Carthew P, Edwards RE, Nolan BM, Tucker MJ, Smith LL: Compartmentalized uterotrophic effects of tamoxifen, toremifene, and estradiol in the ovariectomized Wistar (Han) rat. Toxicol Sci. 1999, 48: 197-205.PubMedView Article
- Kohlerova E, Skarda J: Mouse bioassay to assess oestrogenic and anti-oestrogenic compounds: hydroxytamoxifen, diethylstilbestrol and genistein. J Vet Med A Physiol Pathol Clin Med. 2004, 51: 209-217.PubMedView Article
- Osborne CK, Zhao H, Fuqua SA: Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol. 2000, 18: 3172-3186.PubMed
- Lewis JS, Jordan VC: Selective estrogen receptor modulators (SERMs): Mechanisms of anticarcinogenesis and drug resistance. Mutat Res. 2005, 591: 247-263.PubMedView Article
- Smith CL, Nawaz Z, O'Malley BW: Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol. 1997, 11: 657-666.PubMedView Article
- Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Wade JL, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N: Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. Jama. 2006, 295: 2727-2741.PubMedView Article
- Reel JR, Lamb IJ, Neal BH: Survey and assessment of mammalian estrogen biological assays for hazard characterization. Fundam Appl Toxicol. 1996, 34: 288-305.PubMedView Article
- Jordan VC, Collins MM, Rowsby L, Prestwich G: A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol. 1977, 75: 305-316.PubMedView Article
- Boverhof DR, Fertuck KC, Burgoon LD, Eckel JE, Gennings C, Zacharewski TR: Temporal- and dose-dependent hepatic gene expression changes in immature ovariectomized mice following exposure to ethynyl estradiol. Carcinogenesis. 2004, 25: 1277-1291.PubMedView Article
- Fertuck KC, Eckel JE, Gennings C, Zacharewski TR: Identification of temporal patterns of gene expression in the uteri of immature, ovariectomized mice following exposure to ethynylestradiol. Physiol Genomics. 2003, 15: 127-141.PubMedView Article
- Kwekel JC, Burgoon LD, Burt JW, Harkema JR, Zacharewski TR: A cross-species analysis of the rodent uterotrophic program: elucidation of conserved responses and targets of estrogen signaling. Physiol Genomics. 2005, 23: 327-342.PubMedView Article
- Van den Belt K, Berckmans P, Vangenechten C, Verheyen R, Witters H: Comparative study on the in vitro/in vivo estrogenic potencies of 17beta-estradiol, estrone, 17alpha-ethynylestradiol and nonylphenol. Aquat Toxicol. 2004, 66: 183-195.PubMedView Article
- Carthew P, Edwards RE, Nolan BM: Uterotrophic effects of tamoxifen, toremifene, and raloxifene do not predict endometrial cell proliferation in the ovariectomized CD1 mouse. Toxicol Appl Pharmacol. 1999, 158: 24-32.PubMedView Article
- Jordan VC, Dix CJ, Naylor KE, Prestwich G, Rowsby L: Nonsteroidal antiestrogens: their biological effects and potential mechanisms of action. J Toxicol Environ Health. 1978, 4: 363-390.PubMedView Article
- Jordan VC, Dix CJ: Effect of oestradiol benzoate, tamoxifen and monohydroxytamoxifen on immature rat uterine progesterone receptor synthesis and endometrial cell division. J Steroid Biochem. 1979, 11: 285-291.PubMedView Article
- Loeb L, Suntzeff V, Burns EL: Growth processes induced by estrogenic hormones in the uterus of the mouse. Am J Cancer. 1938, 34: 413-427.PubMed
- Moggs JG, Tinwell H, Spurway T, Chang HS, Pate I, Lim FL, Moore DJ, Soames A, Stuckey R, Currie R, Zhu T, Kimber I, Ashby J, Orphanides G: Phenotypic anchoring of gene expression changes during estrogen-induced uterine growth. Environ Health Perspect. 2004, 112: 1589-1606.PubMed CentralPubMedView Article
- Yuen T, Wurmbach E, Pfeffer RL, Ebersole BJ, Sealfon SC: Accuracy and calibration of commercial oligonucleotide and custom cDNA microarrays. Nucleic Acids Res. 2002, 30: e48-PubMed CentralPubMedView Article
- Bourdeau V, Deschenes J, Metivier R, Nagai Y, Nguyen D, Bretschneider N, Gannon F, White JH, Mader S: Genome-wide identification of high-affinity estrogen response elements in human and mouse. Mol Endocrinol. 2004, 18: 1411-1427.PubMedView Article
- Black LJ, Goode RL: Uterine bioassay of tamoxifen, trioxifene and a new estrogen antagonist (LY117018) in rats and mice. Life Sci. 1980, 26: 1453-1458.PubMedView Article
- Fromson JM, Pearson S, Bramah S: The metabolism of tamoxifen (I.C.I. 46,474). I. In laboratory animals. Xenobiotica. 1973, 3: 693-709.PubMedView Article
- Fromson JM, Pearson S, Bramah S: The metabolism of tamoxifen (I.C.I. 46,474). II. In female patients. Xenobiotica. 1973, 3: 711-714.PubMedView Article
- Robinson SP, Langan-Fahey SM, Johnson DA, Jordan VC: Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug Metab Dispos. 1991, 19: 36-43.PubMed
- Kiriwat O, Fotherby K: Pharmacokinetics of oral contraceptive steroids after morning or evening administration. Contraception. 1983, 27: 153-160.PubMedView Article
- Gray CA, Bartol FF, Tarleton BJ, Wiley AA, Johnson GA, Bazer FW, Spencer TE: Developmental biology of uterine glands. Biol Reprod. 2001, 65: 1311-1323.PubMedView Article
- Sanyal A, Riggs BL, Spelsberg TC, Khosla S: Bone marrow stromal cells express two distinct splice variants of ER-alpha that are regulated by estrogen. J Cell Biochem. 2005, 94: 88-97.PubMedView Article
- Boverhof DR, Burgoon LD, Tashiro C, Chittim B, Harkema JR, Jump DB, Zacharewski TR: Temporal and dose-dependent hepatic gene expression patterns in mice provide new insights into TCDD-Mediated hepatotoxicity. Toxicol Sci. 2005, 85: 1048-1063.PubMedView Article
- Naciff JM, Overmann GJ, Torontali SM, Carr GJ, Tiesman JP, Richardson BD, Daston GP: Gene expression profile induced by 17 alpha-ethynyl estradiol in the prepubertal female reproductive system of the rat. Toxicol Sci. 2003, 72: 314-330.PubMedView Article
- Yamashita S, Takayanagi A, Shimizu N: Temporal and cell-type specific expression of c-fos and c-jun protooncogenes in the mouse uterus after estrogen stimulation. Endocrinology. 1996, 137: 5468-5475.PubMed
- Fan TJ, Han LH, Cong RS, Liang J: Caspase family proteases and apoptosis. Acta Biochim Biophys Sin (Shanghai). 2005, 37: 719-727.View Article
- Lai MD, Jiang MJ, Wing LY: Estrogen stimulates expression of p21Waf1/Cip1 in mouse uterine luminal epithelium. Endocrine. 2002, 17: 233-239.PubMedView Article
- Kirkland JL, Murthy L, Stancel GM: Tamoxifen stimulates expression of the c-fos proto-oncogene in rodent uterus. Mol Pharmacol. 1993, 43: 709-714.PubMed
- Mylonas I, Jeschke U, Wiest I, Hoeing A, Vogl J, Shabani N, Kuhn C, Schulze S, Kupka MS, Friese K: Inhibin/activin subunits alpha, beta-A and beta-B are differentially expressed in normal human endometrium throughout the menstrual cycle. Histochem Cell Biol. 2004, 122: 461-471.PubMedView Article
- Nakayama H, Sano T, Motegi A, Oyama T, Nakajima T: Increasing 14-3-3 sigma expression with declining estrogen receptor alpha and estrogen-responsive finger protein expression defines malignant progression of endometrial carcinoma. Pathol Int. 2005, 55: 707-715.PubMedView Article
- Krebs J, Saremaslani P, Caduff R: ALG-2: a Ca2+ -binding modulator protein involved in cell proliferation and in cell death. Biochim Biophys Acta. 2002, 1600: 68-73.PubMedView Article
- Fernandez-Zapico ME, Gonzalez-Paz NC, Weiss E, Savoy DN, Molina JR, Fonseca R, Smyrk TC, Chari ST, Urrutia R, Billadeau DD: Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumorigenesis. Cancer Cell. 2005, 7: 39-49.PubMedView Article
- Mehus JG, Deloukas P, Lambeth DO: NME6: a new member of the nm23/nucleoside diphosphate kinase gene family located on human chromosome 3p21.3. Hum Genet. 1999, 104: 454-459.PubMedView Article
- Rampazzo C, Kost-Alimova M, Ruzzenente B, Dumanski JP, Bianchi V: Mouse cytosolic and mitochondrial deoxyribonucleotidases: cDNA cloning of the mitochondrial enzyme, gene structures, chromosomal mapping and comparison with the human orthologs. Gene. 2002, 294: 109-117.PubMedView Article
- Jablonski EM, McConnell NA, Hughes FM, Huet-Hudson YM: Estrogen regulation of aquaporins in the mouse uterus: potential roles in uterine water movement. Biol Reprod. 2003, 69: 1481-1487.PubMedView Article
- Koyama N, Ishibashi K, Kuwahara M, Inase N, Ichioka M, Sasaki S, Marumo F: Cloning and functional expression of human aquaporin8 cDNA and analysis of its gene. Genomics. 1998, 54: 169-172.PubMedView Article
- McMahon RJ, Cousins RJ: Mammalian zinc transporters. J Nutr. 1998, 128: 667-670.PubMed
- Suzuki T, Ishihara K, Migaki H, Matsuura W, Kohda A, Okumura K, Nagao M, Yamaguchi-Iwai Y, Kambe T: Zinc transporters, ZnT5 and ZnT7, are required for the activation of alkaline phosphatases, zinc-requiring enzymes that are glycosylphosphatidylinositol-anchored to the cytoplasmic membrane. J Biol Chem. 2005, 280: 637-643.PubMedView Article
- Lee JY, Kim JH, Hong SH, Cherny RA, Bush AI, Palmiter RD, Koh JY: Estrogen decreases zinc transporter 3 expression and synaptic vesicle zinc levels in mouse brain. J Biol Chem. 2004, 279: 8602-8607.PubMedView Article
- Burckhardt BC, Burckhardt G: Transport of organic anions across the basolateral membrane of proximal tubule cells. Rev Physiol Biochem Pharmacol. 2003, 146: 95-158.PubMedView Article
- Ljubojevic M, Balen D, Breljak D, Kusan M, Anzai N, Bahn A, Burckhardt G, Sabolic I: Renal expression of organic anion transporter OAT2 in rats and mice is regulated by sex hormones. Am J Physiol Renal Physiol. 2006
- Inoue A, Yoshida N, Omoto Y, Oguchi S, Yamori T, Kiyama R, Hayashi S: Development of cDNA microarray for expression profiling of estrogen-responsive genes. J Mol Endocrinol. 2002, 29: 175-192.PubMedView Article
- del Carmen Garcia Molina Wolgien M, da Silva ID, Villanova FE, Yumi Otsuka A, Borra RC, Lima Reis LF, Carvalho AF, Baracat EC, Gebrim LH: Differential gene expression assessed by cDNA microarray analysis in breast cancer tissue under tamoxifen treatment. Eur J Gynaecol Oncol. 2005, 26: 501-504.PubMed
- Scafoglio C, Ambrosino C, Cicatiello L, Altucci L, Ardovino M, Bontempo P, Medici N, Molinari AM, Nebbioso A, Facchiano A, Calogero RA, Elkon R, Menini N, Ponzone R, Biglia N, Sismondi P, Bortoli MD, Weisz A: Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells. J Cell Biochem. 2006
- Gadal F, Starzec A, Bozic C, Pillot-Brochet C, Malinge S, Ozanne V, Vicenzi J, Buffat L, Perret G, Iris F, Crepin M: Integrative analysis of gene expression patterns predicts specific modulations of defined cell functions by estrogen and tamoxifen in MCF7 breast cancer cells. J Mol Endocrinol. 2005, 34: 61-75.PubMedView Article
- Frasor J, Stossi F, Danes JM, Komm B, Lyttle CR, Katzenellenbogen BS: Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res. 2004, 64: 1522-1533.PubMedView Article
- Frasor J, Chang EC, Komm B, Lin CY, Vega VB, Liu ET, Miller LD, Smeds J, Bergh J, Katzenellenbogen BS: Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Res. 2006, 66: 7334-7340.PubMedView Article
- Hodges LC, Cook JD, Lobenhofer EK, Li L, Bennett L, Bushel PR, Aldaz CM, Afshari CA, Walker CL: Tamoxifen functions as a molecular agonist inducing cell cycle-associated genes in breast cancer cells. Mol Cancer Res. 2003, 1: 300-311.PubMed
- Green AR, Styles JA, Parrott EL, Gray D, Edwards RE, Smith AG, Gant TW, Greaves P, Al-Azzawi F, White IN: Neonatal tamoxifen treatment of mice leads to adenomyosis but not uterine cancer. Exp Toxicol Pathol. 2005, 56: 255-263.PubMedView Article
- Robertson DW, Katzenellenbogen JA, Hayes JR, Katzenellenbogen BS: Antiestrogen basicity--activity relationships: a comparison of the estrogen receptor binding and antiuterotrophic potencies of several analogues of (Z)-1,2-diphenyl-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-butene (tamoxifen, Nolvadex) having altered basicity. J Med Chem. 1982, 25: 167-171.PubMedView Article
- Dowsett M, Haynes BP: Hormonal effects of aromatase inhibitors: focus on premenopausal effects and interaction with tamoxifen. J Steroid Biochem Mol Biol. 2003, 86: 255-263.PubMedView Article
- Giambiagi N, Pasqualini JR: Immunological differences between the estradiol-, tamoxifen- and 4-hydroxy-tamoxifen-estrogen receptor complexes detected by two monoclonal antibodies. J Steroid Biochem. 1988, 30: 213-217.PubMedView Article
- Webb P, Nguyen P, Kushner PJ: Differential SERM effects on corepressor binding dictate ERalpha activity in vivo. J Biol Chem. 2003, 278: 6912-6920.PubMedView Article
- McDonnell DP, Chang CY, Norris JD: Development of peptide antagonists that target estrogen receptor-cofactor interactions. J Steroid Biochem Mol Biol. 2000, 74: 327-335.PubMedView Article
- Geum D, Sun W, Paik SK, Lee CC, Kim K: Estrogen-induced cyclin D1 and D3 gene expressions during mouse uterine cell proliferation in vivo: differential induction mechanism of cyclin D1 and D3. Mol Reprod Dev. 1997, 46: 450-458.PubMedView Article
- Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL: The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell. 1998, 95: 927-937.PubMedView Article
- Das D, Peterson RC, Scovell WM: High mobility group B proteins facilitate strong estrogen receptor binding to classical and half-site estrogen response elements and relax binding selectivity. Mol Endocrinol. 2004, 18: 2616-2632.PubMedView Article
- Kazmin D, Prytkova T, Cook CE, Wolfinger R, Chu TM, Beratan D, Norris JD, Chang CY, McDonnell DP: Linking ligand-induced alterations in androgen receptor structure to differential gene expression: a first step in the rational design of selective androgen receptor modulators. Mol Endocrinol. 2006, 20: 1201-1217.PubMedView Article
- Meijer OC, Kalkhoven E, van der Laan S, Steenbergen PJ, Houtman SH, Dijkmans TF, Pearce D, de Kloet ER: Steroid receptor coactivator-1 splice variants differentially affect corticosteroid receptor signaling. Endocrinology. 2005, 146: 1438-1448.PubMedView Article
- Lim CK, Yuan ZX, Lamb JH, White IN, De Matteis F, Smith LL: A comparative study of tamoxifen metabolism in female rat, mouse and human liver microsomes. Carcinogenesis. 1994, 15: 589-593.PubMedView Article
- White IN: Tamoxifen: is it safe? Comparison of activation and detoxication mechanisms in rodents and in humans. Curr Drug Metab. 2003, 4: 223-239.PubMedView Article
- Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Weinshilboum RM, Fritcher EG, Nibbe AM, Desta Z, Nguyen A, Flockhart DA, Perez EA, Ingle JN: The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007, 101: 113-121.PubMedView Article
- Deligdisch L, Kalir T, Cohen CJ, de Latour M, Le Bouedec G, Penault-Llorca F: Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer. Gynecol Oncol. 2000, 78: 181-186.PubMedView Article
- Mourits MJ, De Vries EG, Willemse PH, Ten Hoor KA, Hollema H, Van der Zee AG: Tamoxifen treatment and gynecologic side effects: a review. Obstet Gynecol. 2001, 97: 855-866.PubMedView Article
- Human Pathology @ Michigan State University. [http://www.humanpathology.msu.edu/histology]
- Research Technology Support Facility. [http://www.genomics.msu.edu]
- Rockett JC, Dix DJ: Application of DNA arrays to toxicology. Environ Health Perspect. 1999, 107: 681-685.PubMed CentralPubMedView Article
- dbZACH Home Page: Zacharewski Laboratory. [http://dbzach.fst.msu.edu/]
- Burgoon LD, Eckel-Passow JE, Gennings C, Boverhof DR, Burt JW, Fong CJ, Zacharewski T: Protocols for the Assurance of Microarray Data Quality and Process Control. Nucleic Acids Research. 2005, 33: e172-PubMed CentralPubMedView Article
- Eckel JE, Gennings C, Therneau TM, Burgoon LD, Boverhof DR, Zacharewski TR: Normalization of two-channel microarray experiments: a semiparametric approach. Bioinformatics. 2005, 21: 1078-1083.PubMedView Article
- Eckel JE, Gennings C, Chinchilli VM, Burgoon LD, Zacharewski TR: Empirical bayes gene screening tool for time-course or dose-response microarray data. J Biopharm Stat. 2004, 14: 647-670.PubMedView Article
- Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C, Aach J, Ansorge W, Ball CA, Causton HC, Gaasterland T, Glenisson P, Holstege FC, Kim IF, Markowitz V, Matese JC, Parkinson H, Robinson A, Sarkans U, Schulze-Kremer S, Stewart J, Taylor R, Vilo J, Vingron M: Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet. 2001, 29: 365-371.PubMedView Article
- Burgoon LD, Boutros PC, Dere E, Zacharewski TR: dbZach: A MIAME-Compliant Toxicogenomic Supportive Relational Database. Toxicol Sci. 2005
- Primer3 Input (primer3/input.htm version 0.3.0 modified for WI). [http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi]
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.